Gilead Sciences and Novo Nordisk are to collaborate on a clinical trial, and possibly on preclinical research for nonalcoholic steatohepatitis, a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver, which can lead to scarring or fibrosis. The clinical trial will combine Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH.
Mads Krogsgaard Thomsen, Chief Science Officer and Executive Vice President of Novo Nordisk, said: “We are very pleased about the potential to enter into this clinical collaboration with Gilead, which would combine Novo Nordisk’s semaglutide program in NASH with Gilead’s clinical programs to provide novel approaches for the treatment of NASH. By combining the leading molecular science and clinical expertise of our two companies within the rapidly expanding liver and metabolic diseases, we aim to develop innovative, new and effective combination therapies to help people with NASH.”
“Novo Nordisk and Gilead to partner on NASH clinical trial.“
John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development at Gilead Sciences, said: “NASH is a complex disease that often affects people with diabetes and metabolic syndrome. Currently, patients living with NASH have limited treatment options. We are excited to work with Novo Nordisk on this important collaboration, which would bring together Novo Nordisk’s broad expertise related to diabetes and metabolism and Gilead’s expertise in both liver disease and combination therapies. We look forward to working with the Novo Nordisk team to explore opportunities to advance our complementary research capabilities and approaches in NASH to help address this significant unmet need for patients.”